Skadden, Freshfields and Davis Polk take the lead as blockbuster Pfizer/AstraZeneca deal gears up again

Jaishree Kalia · 28 April 2014 · 2 min read

Corporate and M&A Davis Polk Freshfields Skadden, Arps, Slate, Meagher & Flom

Skadden, Arps, Slate, Meagher & Flom, Freshfields Bruckhaus Deringer and Davis Polk & Wardwell have all landed lead roles advising Pfizer and AstraZeneca as talks over a potential $100bn merger resurface.

This article is for Legal Business subscribers. Please log in or subscribe to read on.

Related Content

US pair lead on $115bn tech megadeal

City reacts to a ‘pedestrian’ Budget

Weil in numbers: the remaining partner bench

Cravath makes rare London partner promotion amid 11-strong round

Sidley in talks to take Weil Paris office alongside heavyweight PE partners in London and Germany

Slaughters leads for Anthropic on UK share offer in IPO

Revolving doors: Simpson Thacher, Latham, Sidley lead New Year London moves

Five partners vie to succeed Hoyland as Simmons managing partner

‘Seize every opportunity’ – Paul Hastings partner Reena Gogna on City law, Suits and poetry